Portal de Periódicos da CAPES

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma

2016; Impact Journals LLC; Volume: 7; Issue: 41 Linguagem: Inglês

10.18632/oncotarget.10704

1949-2553

Anna Maria Rachiglio, Riziero Esposito Abate, Alessandra Sacco, Raffaella Pasquale, Francesca Fenizia, Matilde Lambiase, Alessandro Morabito, Agnese Montanino, Gaetano Rocco, Carmen Romano, Anna Nappi, Rosario Vincenzo Iaffaioli, Fabiana Tatangelo, Gerardo Botti, Fortunato Ciardiello, Monica R. Maiello, Antonella De Luca, Nicola Normanno,

Lung Cancer Treatments and Mutations

// Anna Maria Rachiglio 1 , Riziero Esposito Abate 1 , Alessandra Sacco 1 , Raffaella Pasquale 1 , Francesca Fenizia 1 , Matilde Lambiase 1 , Alessandro Morabito 2 , Agnese Montanino 2 , Gaetano Rocco 3 , Carmen Romano 4 , Anna Nappi 4 , Rosario Vincenzo Iaffaioli 4 , Fabiana Tatangelo 5 , Gerardo Botti 5 , Fortunato Ciardiello 6 , Monica R. Maiello 7 , Antonella De Luca 7 , Nicola Normanno 1, 7 1 Laboratory of Pharmacogenomics, CROM-Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy 2 Thoraco-Pulmonary, Medical Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy 3 Thoracic Surgery, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy 4 Gastro-Intestinal Medical Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy 5 Surgical Pathology Unit, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy 6 Department of Clinical and Experimental Medicine 'F. Magrassi'-Medical Oncology, Seconda Università degli Studi di Napoli, Napoli, Italy 7 Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy Correspondence to: Nicola Normanno, email: nicnorm@yahoo.com , n.normanno@istitutotumori.na.it Keywords: targeted sequencing, colon cancer, lung cancer, liquid biopsy, driver mutations Received: April 26, 2016 Accepted: May 29, 2016 Published: July 19, 2016 ABSTRACT The circulating free tumor DNA (ctDNA) represents an alternative, minimally invasive source of tumor DNA for molecular profiling. Targeted sequencing with next generation sequencing (NGS) can assess hundred mutations starting from a low DNA input. We performed NGS analysis of ctDNA from 44 patients with metastatic non-small-cell lung carcinoma (NSCLC) and 35 patients with metastatic colorectal carcinoma (CRC). NGS detected EGFR mutations in 17/22 plasma samples from EGFR-mutant NSCLC patients (sensitivity 77.3%). The concordance rate between tissue and plasma in NSCLC was much lower for other mutations such as KRAS that, based on the allelic frequency and the fraction of neoplastic cells, were likely to be sub-clonal. NGS also identified EGFR mutations in plasma samples from two patients with EGFR wild type tumor tissue. Both mutations were confirmed by droplet digital PCR (ddPCR) in both plasma and tissue samples. In CRC, the sensitivity of the NGS plasma analysis for RAS mutations was 100% (6/6) in patients that had not resection of the primary tumor before blood drawing, and 46.2% (6/13) in patients with primary tumor resected before enrollment. Our study showed that NGS is a suitable method for plasma testing. However, its clinical sensitivity is significantly affected by the presence of the primary tumor and by the heterogeneity of driver mutations.